Distribution agreement signed for the Finnish, Norwegian and Swedish markets

Hemcheck Sweden AB has signed a distributor agreement with Vingmed, one of the largest distributors in the Nordic region. The agreement entails an initial order like previous similar agreements.

– Vingmed is a large and well-established distributor in the Nordic region and has a broad network in the market. We believe that the time is right to switch to distribution in our home markets and we will work closely with Vingmed to ensure that we together take advantage of both organizations’ customer contacts. We hope that the collaboration will be successful and look forward to starting the work together, says Joen Averstad, CEO of Hemcheck.

– We are pleased to sign this agreement with Hemcheck. We have had a dialogue over a longer period of time, and we believe that the products have good market potential and they also fit well into our portfolio of products. We look forward to starting the sales and marketing work, says Kasper Hermansen, Business Development Manager Lab, at Vingmed.

For further information contact:

Hemcheck Sweden AB (publ)

Joen Averstad, CEO

Tel: +46 76 108 8191

Email: joen.averstad@hemcheck.com 

About Vingmed

Vingmed was formed in 1968 in Norway. The Vingmed group is today one of the Nordic region’s largest sales companies within cardiology, radiology, endoscopy, intensive care, medical IT / imaging and surgery / Lab. The Swedish operations were established in 1979, in Denmark the company was established in 1991 and later in Finland in 2017. All companies within the Vingmed group are certified against ISO 9001:2008. Vingmed represents several large relevant companies such as Werfen and Swisslog Healthcare.

Read more at: https://www.vingmed.se/

About Hemcheck

Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolysed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is listed on the Nasdaq First North Growth Market.

FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.